China’s NMPA reviews vaccine regulatory QMS

The Chinese National Medical Products Administration (NMPA) held a meeting recently to carry out the 2023 annual review of the vaccine regulatory quality management system (QMS).

The NMPA’s Commissioner Li Li chaired the meeting and evaluated the suitability, adequacy and effectiveness of the NMPA's vaccine regulatory QMS.

The establishment and operation of the vaccine regulatory QMS represents a major effort to meet the assessment requirements of the National Regulatory Authority (NRA) for vaccines of the World Health Organization (WHO) and to enhance the national vaccine regulatory capabilities.